Open AccessThe Predictive Significance of the Advanced Lung Cancer Inflammation Index (ALI) in Patients with Melanoma Treated with Immunotherapy as Second-Line Therapy
Author(s) -
Xi Cheng,
Yong Dong,
Fang Lou
Publication year - 2021
Publication title -
cancer management and research
Language(s) - English
Resource type - Journals
ISSN - 1179-1322
DOI - 10.2147/cmar.s286453
Subject(s) - medicine , absolute neutrophil count , body mass index , gastroenterology , immunotherapy , oncology , melanoma , cancer , retrospective cohort study , lung cancer , receiver operating characteristic , neutrophil to lymphocyte ratio , c reactive protein , lymphocyte , inflammation , neutropenia , chemotherapy , cancer research
The advanced lung cancer inflammation index (ALI) is a useful tool to predict the clinical outcome in several malignancies. The ALI not only contains indices related to inflammation but also the body mass index (BMI), which was reported to correlate with the sarcopenic status. However, to date, its predictive significance in metastatic melanoma patients treated with second-line immunotherapy has not been evaluated.